Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myeloma

Multiple myeloma (MM) is a clonal plasma cell malignancy characterized by clinical heterogeneity, high relapse rates, and eventual drug resistance despite advances in therapy. Over the past two decades, phase 3 clinical trials have redefined MM management by integrating novel agents, monoclonal anti...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sandeep Singh, Vivek Uttam, Shafiul Haque, Hardeep Singh Tuli, Pallavi Mishra, Aklank Jain
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-01-01
Col·lecció:	Cancer Treatment and Research Communications
Matèries:	Multiple Myeloma Trial outcomes Relapsed/Refractory Multiple Myeloma Minimal Residual Disease Clonal Plasma Cell Bone Marrow
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2468294225001777
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!